^
    Back
    Association details:
    Biomarker:EGFR E746
    Cancer:Non Small Cell Lung Cancer
    Drug:Tagrisso (osimertinib) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Transl Lung Cancer Res
    Title:

    EGFR mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients

    Published date:
    03/13/2020
    Excerpt:
    We found ΔE746 tumors had a significantly higher ORR and CBR compared with L858R tumors (ORR: 64.9% vs. 47.3%, P=0.014; CBR: 86.6% vs. 73.1%, respectively, P=0.020)…verall, these data suggested that patients with EGFR ΔE746 tumors have a significantly better benefit from osimertinib treatment.
    DOI:
    10.21037/tlcr.2020.03.35